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Megakaryocytes both from primary myelofibrosis patients (PMF) and the 
Gata1low mouse model express levels of TGF-β 3-4-fold (p<0.001) greater than nor-
mal, suggesting that increased release of TGF-β from these cells in the microenviron-
ment may play an important role in disease progression. To test this hypothesis, 12 
Gata1low mice were treated for 4 cycles with SB431542 (C22H16N4O3, MW=384.4), 
an inhibitor of TGF- β1/activin receptor-like kinases, for a total of 2 months. Mice 
were then sacrifi ced and analyzed for disease progression. In the blood, SB431542-
treatment signifi cantly increased platelet numbers (by 2-fold) and reduced white 
blood cell counts (20%) and poikilocyte frequencies (by 90%) without aff ecting hema-
tocrit levels (which remained normal) or progenitor cell traffi  cking (which remained 
high). In the marrow, SB431542-treatment signifi cantly increased total cell numbers 
[>2-fold] and frequency of progenitor cells (by 2-fold) and erythroid and megakary-
ocytic (by >50%) precursors while reducing fi brosis (>90%) and microvessel density 
(>90%). In addition, SB431542-treatment
reduced spleen weight by 50% and erythroblast and/or megakaryocyte frequen-
cies in spleen and liver by 50%. Therefore, in the Gata1low mouse model inhibition of 
TGF-β1 effi  ciently reactivates hematopoiesis in marrow while reducing hematopoiesis 
in extramedullary sites suggesting a potential benefi t for treatments targeting micro-
environment abnormalities in PMF.
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